BerGenBio ASA (OTCMKTS:BRRGF) was the target of a significant growth in short interest in the month of April. As of April 15th, there was short interest totalling 346,900 shares, a growth of 29.4% from the March 31st total of 268,100 shares. Based on an average daily trading volume, of 0 shares, the short-interest ratio is presently ? days.
Separately, HC Wainwright reiterated a “buy” rating on shares of BerGenBio ASA in a report on Monday, March 8th.
Shares of OTCMKTS:BRRGF remained flat at $$3.52 during midday trading on Tuesday. BerGenBio ASA has a twelve month low of $2.95 and a twelve month high of $4.39. The company’s 50 day simple moving average is $3.52 and its 200 day simple moving average is $3.53.
BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in the developing drugs to treat immune evasive, drug resistant, and metastatic cancers. Its lead candidate is Bemcentinib, a bio-available small molecule AXL inhibitor, which is in Phase II clinical development in major cancer indications and COVID-19.
Recommended Story: Understanding each part of a balance sheet
Receive News & Ratings for BerGenBio ASA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BerGenBio ASA and related companies with MarketBeat.com's FREE daily email newsletter.